MX420940B - Oligonucleótido bicatenario específico del gen de anfirregulina y composición para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo. - Google Patents

Oligonucleótido bicatenario específico del gen de anfirregulina y composición para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.

Info

Publication number
MX420940B
MX420940B MX2020012652A MX2020012652A MX420940B MX 420940 B MX420940 B MX 420940B MX 2020012652 A MX2020012652 A MX 2020012652A MX 2020012652 A MX2020012652 A MX 2020012652A MX 420940 B MX420940 B MX 420940B
Authority
MX
Mexico
Prior art keywords
stranded oligonucleotide
double
preventing
composition
same
Prior art date
Application number
MX2020012652A
Other languages
English (en)
Other versions
MX2020012652A (es
Inventor
Han- Oh PARK
Jun-Hong Park
Pyoung Oh Yoon
Seon Joo Bae
Seung Seob Son
Sung Il Yun
Tae- Rim KIM
Youngho Ko
Original Assignee
Bioneer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer Corp filed Critical Bioneer Corp
Publication of MX2020012652A publication Critical patent/MX2020012652A/es
Publication of MX420940B publication Critical patent/MX420940B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un oligonucleótido bicatenario el cual puede inhibir de forma muy específica y eficazmente una expresión de anfirreguiina y, preferentemente, un oligonucleótido bicatenario que comprende una secuencia en la forma de ARNIARN, ADN/ADN, o un híbrido de ADN/ARN, una estructura de oligonucleótido bicatenario que comprende el oligonucleótido bicatenario, nanopartículas que comprende la estructura de oligonucleótido bicatenario, y un uso preventivo o terapéutico de enfermedades fibrosas o respiratorias del mismo.
MX2020012652A 2018-05-25 2019-05-22 Oligonucleótido bicatenario específico del gen de anfirregulina y composición para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo. MX420940B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180059783 2018-05-25
PCT/KR2019/006144 WO2019225968A1 (ko) 2018-05-25 2019-05-22 엠피레귤린 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물

Publications (2)

Publication Number Publication Date
MX2020012652A MX2020012652A (es) 2021-05-27
MX420940B true MX420940B (es) 2025-02-10

Family

ID=68617387

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012652A MX420940B (es) 2018-05-25 2019-05-22 Oligonucleótido bicatenario específico del gen de anfirregulina y composición para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.

Country Status (12)

Country Link
US (4) US20210189398A1 (es)
EP (1) EP3816285A4 (es)
JP (2) JP7154403B2 (es)
KR (1) KR102746742B1 (es)
CN (2) CN119685309A (es)
AU (2) AU2019272190B2 (es)
BR (1) BR112020023968A2 (es)
MX (1) MX420940B (es)
MY (1) MY199134A (es)
SA (1) SA520420620B1 (es)
WO (1) WO2019225968A1 (es)
ZA (2) ZA202008040B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX420940B (es) 2018-05-25 2025-02-10 Bioneer Corp Oligonucleótido bicatenario específico del gen de anfirregulina y composición para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.
AU2019448656C1 (en) * 2019-05-30 2024-05-30 National Institute Of Biological Sciences, Beijing Drug target of idiopathic pulmonary fibrosis
AU2021252813B2 (en) * 2020-04-10 2025-01-09 Bioneer Corporation Composition using urine sample for diagnosis of kidney disease
EP4151236A4 (en) * 2020-05-14 2024-06-26 Bioneer Corporation Composition for preventing or treating obesity-related disease containing amphiregulin-specific double-stranded oligonucleotide structure
US20230203491A1 (en) * 2020-05-22 2023-06-29 Bioneer Corporation Double-stranded oligonucleotide and composition for treating covid-19 containing same
CN117677402A (zh) * 2021-03-08 2024-03-08 柏业公司 用于使用超声雾化器施用用于预防或治疗包括covid-19的呼吸道病毒感染、由病毒感染引起的肺纤维化或呼吸道疾病的双链寡核苷酸结构的组合物
CN116966302B (zh) * 2023-06-28 2025-11-25 华中科技大学同济医学院附属协和医院 Areg的新用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5034323A (en) 1989-03-30 1991-07-23 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
JP2009504179A (ja) 2005-08-17 2009-02-05 バイオニア コーポレイション ｓｉＲＮＡの細胞内伝達のためのｓｉＲＮＡと親水性高分子との間の接合体、及びその製造方法
AU2007306139B2 (en) 2006-10-11 2014-02-27 Fusion Antibodies Limited Combination therapy
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
KR101224828B1 (ko) 2009-05-14 2013-01-22 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
WO2011132182A1 (en) * 2010-04-18 2011-10-27 Yeda Research And Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
KR101241852B1 (ko) * 2012-06-28 2013-03-11 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
JP2015532100A (ja) 2012-10-05 2015-11-09 バイオニア コーポレイション アンフィレギュリンに特異的な二重鎖オリゴｒｎａ、そのような二重鎖オリゴｒｎａを含む二重鎖オリゴｒｎａの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物
EP3128008B1 (en) * 2014-04-04 2024-05-29 Bioneer Corporation Double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
CA2966092A1 (en) * 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
WO2016204515A1 (ko) * 2015-06-15 2016-12-22 (주)바이오니아 STAT3 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체, 이를 포함하는 조성물 및 이의 용도
MX420940B (es) 2018-05-25 2025-02-10 Bioneer Corp Oligonucleótido bicatenario específico del gen de anfirregulina y composición para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.

Also Published As

Publication number Publication date
EP3816285A1 (en) 2021-05-05
CA3101320A1 (en) 2019-11-28
BR112020023968A2 (pt) 2021-02-23
AU2023201262B2 (en) 2025-08-21
CN112368382B (zh) 2024-11-01
MX2020012652A (es) 2021-05-27
JP7154403B2 (ja) 2022-10-17
JP2021525103A (ja) 2021-09-24
AU2023201262A1 (en) 2023-04-27
JP2023002587A (ja) 2023-01-10
WO2019225968A1 (ko) 2019-11-28
AU2019272190B2 (en) 2022-12-01
EP3816285A4 (en) 2022-03-16
ZA202206418B (en) 2025-08-27
JP7645849B2 (ja) 2025-03-14
US20230203494A1 (en) 2023-06-29
CN112368382A (zh) 2021-02-12
KR102746742B1 (ko) 2024-12-26
US20250207137A1 (en) 2025-06-26
AU2019272190A1 (en) 2020-12-17
SA520420620B1 (ar) 2024-03-17
KR20190134506A (ko) 2019-12-04
US20230332154A1 (en) 2023-10-19
US12037589B2 (en) 2024-07-16
MY199134A (en) 2023-10-17
CN119685309A (zh) 2025-03-25
US20210189398A1 (en) 2021-06-24
ZA202008040B (en) 2023-02-22

Similar Documents

Publication Publication Date Title
ZA202206418B (en) Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
MX2024000208A (es) Restos de administracion terapeutica novedosos y usos de estos.
Guzman-Villanueva et al. Formulation approaches to short interfering RNA and MicroRNA: challenges and implications
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
NZ730296A (en) Modified double-stranded rna agents
MX359548B (es) Agentes de iarn modificados.
MX2012010244A (es) Composiciones y metodos de tratamiento para enfermedad de parkinson mediante transferencia del gen bndf-flag a traves del poliplex de neurotensina a neuronas dopaminergicas nigrales.
SA519401379B1 (ar) علاج فيروس مرتبط بغدة لمرض هنتنجتون
NZ759766A (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
WO2008154482A3 (en) Sirna compositions and methods of use in treatment of ocular diseases
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
IL196921A0 (en) Methods and means for treating dna repeat instability associated genetic disorders
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
MX2016000019A (es) (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias.
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
EA033448B1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
MX2025009778A (es) Composicion farmaceutica de un oligonucleotido antisentido y su uso para el tratamiento del sindrome de angelman
MX2023007319A (es) Vacunas de acido nucleico.
CY1123639T1 (el) Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος
MX388737B (es) Oligonucleótidos terapéuticos.
RU2013121802A (ru) Профилактический или терапевтический агент для лечения фиброза
IL250852B (en) Periodontal preparation
WO2014169087A3 (en) Treatment of proximal spinal muscular atrophy
WO2015188198A3 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta